
Mytos uses proprietary robotics to automate the production of stem cell-derived regenerative medicines. They're hiring an Associate Scientist to run automated cell differentiation processes on its iDEM platform, based on-site in London. This role sits within the UK's lab automation and cell therapy sector.
You rarely get the chance to change an entire industry. But that's the position we find ourselves in. Join us, and you'll help scale cures to patients that need them sooner.
We've developed fully-automated cell manufacturing sites powered by custom robotics - to scale therapies to millions of patients. Last year, patients were cured of diseases like Parkinson's Disease and vision loss using stem-cell derived cells - but today these Regenerative Medicines are produced by hand, meaning they're too expensive and hard to scale. With our automated CDMO, these therapies can now be scaled globally at low cost.
We've announced partnerships across multiple therapies so far ranging from Parkinson's, to hearing loss, to bone repair - and raised $24m to expand into the market faster, and accelerate our development! Within the next 12-18 months, neurons grown on our machines will be going into Parkinson's patient brains.
We've assembled a world-class team to take on this challenge, with ex-Dyson engineers and Nature-published scientists working hand-in-hand. You can learn more about your potential Mytos teammates here: Team
Mytos is backed by Y Combinator, the most successful startup program in the world which produced companies such as AirBnb, Dropbox, and Ginkgo Bioworks.
We are looking for a hands-on Associate Scientist to join our Biology team and help push the limits of automation in cell therapy manufacture. . You'll work alongside our scientists and engineers, with mentoring from senior scientists, and generate the data that shapes how our processes and platforms develop. Your work will feed directly into process development, new platform R&D and the running of the lab that makes it all possible.
This is a unique opportunity to build your career at the interface of engineering and biology. You'll start with well-defined, SOP-based work packages and, through structured training grow towards independent execution.
Required:
Desired:
Mytos automates the production of stem cell-derived regenerative medicines using proprietary robotics. Founded in 2016 by Ali Afshar and Ignacio Willats, who met during Afshar's PhD at Imperial College where he became frustrated by manual laboratory processes and began building robots to automate repetitive tasks. The platform takes stem cells (iPSCs) and fully automates their differentiation into specific cell types such as neurons and cardiac cells, replacing manual touchpoints with precisely controlled, programmable steps. In 2023, Mytos closed a $19M Series A led by Buckley Ventures, joined by IQ Capital and Wing VC. The company has launched its iDEM platform as an automated contract development and manufacturing organisation, with its first facility at the Cell and Gene Therapy Catapult's Stevenage Manufacturing Innovation Centre targeting clinical readiness by September 2026.